Terms: = Germ cell tumor AND SOCS1, O15524, 8651, ENSG00000185338, SOCS-1, SSI-1, SSI1, Cish1, JAB, CISH1, CIS1, TIP3 AND Treatment
17 results:
1. Synthetic High-Density Lipoprotein-Based Nanomedicine to Silence socs1 in tumor Microenvironment and Trigger Antitumor Immunity against Glioma.
Yang C; Li Y; Yang Y; Ni Q; Zhang Z; Chai Y; Li J
Angew Chem Int Ed Engl; 2023 Dec; 62(49):e202312603. PubMed ID: 37847126
[TBL] [Abstract] [Full Text] [Related]
2. [miR-155-5p alleviates lipopolysaccharide-induced inflammatory damage of human SH-SY5Y neuroblastoma cells by down-regulating socs1].
Zhou H; Zhou L; Zhang C; Zhou L; Han Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Mar; 39(3):220-229. PubMed ID: 36946346
[TBL] [Abstract] [Full Text] [Related]
3. Epigenomic and transcriptomic landscaping unraveled candidate repositioned therapeutics for non-functioning pituitary neuroendocrine tumors.
Aydin B; Beklen H; Arga KY; Bayrakli F; Turanli B
J Endocrinol Invest; 2023 Apr; 46(4):727-747. PubMed ID: 36306107
[TBL] [Abstract] [Full Text] [Related]
4. National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States.
Ostrom QT; Shoaf ML; Cioffi G; Waite K; Kruchko C; Wen PY; Brat DJ; Barnholtz-Sloan JS; Iorgulescu JB
Neuro Oncol; 2023 Apr; 25(4):799-807. PubMed ID: 35994777
[TBL] [Abstract] [Full Text] [Related]
5. Radiotherapy resistance acquisition in Glioblastoma. Role of socs1 and SOCS3.
Ventero MP; Fuentes-Baile M; Quereda C; Perez-Valeciano E; Alenda C; Garcia-Morales P; Esposito D; Dorado P; Manuel Barbera V; Saceda M
PLoS One; 2019; 14(2):e0212581. PubMed ID: 30811476
[TBL] [Abstract] [Full Text] [Related]
6. Suppressor of cytokine signalling-1 induces significant preclinical antitumor effect in malignant melanoma cells.
Tagami-Nagata N; Serada S; Fujimoto M; Tanemura A; Nakatsuka R; Ohkawara T; Murota H; Kishimoto T; Katayama I; Naka T
Exp Dermatol; 2015 Nov; 24(11):864-71. PubMed ID: 26173926
[TBL] [Abstract] [Full Text] [Related]
7. Effects of suppressor of cytokine signaling 1 silencing on human melanoma cell proliferation and interferon-γ sensitivity.
Xu Y; Wang W; Gou A; Li H; Tian Y; Yao M; Yang R
Mol Med Rep; 2015 Jan; 11(1):583-8. PubMed ID: 25322862
[TBL] [Abstract] [Full Text] [Related]
8. The helicase HAGE prevents interferon-α-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of socs1.
Mathieu MG; Miles AK; Ahmad M; Buczek ME; Pockley AG; Rees RC; Regad T
Cell Death Dis; 2014 Feb; 5(2):e1061. PubMed ID: 24525737
[TBL] [Abstract] [Full Text] [Related]
9. Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study).
Busse A; Rapion J; Fusi A; Suciu S; Nonnenmacher A; Santinami M; Kruit WH; Testori A; Punt CJ; Dalgleish AG; Spatz A; Eggermont AM; Keilholz U
Cancer Immunol Immunother; 2013 Jul; 62(7):1223-33. PubMed ID: 23624802
[TBL] [Abstract] [Full Text] [Related]
10. Enhanced anti-tumor activity of interferon-alpha in socs1-deficient mice is mediated by CD4⁺ and CD8⁺ T cells.
Guenterberg KD; Lesinski GB; Mundy-Bosse BL; Karpa VI; Jaime-Ramirez AC; Wei L; Carson WE
Cancer Immunol Immunother; 2011 Sep; 60(9):1281-8. PubMed ID: 21604070
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme.
Martini M; Pallini R; Luongo G; Cenci T; Lucantoni C; Larocca LM
Int J Cancer; 2008 Dec; 123(12):2955-60. PubMed ID: 18770864
[TBL] [Abstract] [Full Text] [Related]
12. Epigenetic lesions in malignant melanoma.
Schwabe M; Lübbert M
Curr Pharm Biotechnol; 2007 Dec; 8(6):382-7. PubMed ID: 18289047
[TBL] [Abstract] [Full Text] [Related]
13. Development of IFN-gamma resistance is associated with attenuation of SOCS genes induction and constitutive expression of SOCS 3 in melanoma cells.
Fojtova M; Boudny V; Kovarik A; Lauerova L; Adamkova L; Souckova K; Jarkovsky J; Kovarik J
Br J Cancer; 2007 Jul; 97(2):231-7. PubMed ID: 17579625
[TBL] [Abstract] [Full Text] [Related]
14. The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific.
Kissel CK; Schadendorf D; Röckmann H
Melanoma Res; 2006 Dec; 16(6):527-35. PubMed ID: 17119454
[TBL] [Abstract] [Full Text] [Related]
15. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract] [Full Text] [Related]
16. Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells.
Młynarczuk-Biały I; Roeckmann H; Kuckelkorn U; Schmidt B; Umbreen S; Gołab J; Ludwig A; Montag C; Wiebusch L; Hagemeier C; Schadendorf D; Kloetzel PM; Seifert U
Cancer Res; 2006 Aug; 66(15):7598-605. PubMed ID: 16885359
[TBL] [Abstract] [Full Text] [Related]
17. Aliphatic and alicyclic diols induce melanogenesis in cultured cells and guinea pig skin.
Brown DA; Ren WY; Khorlin A; Lesiak K; Conklin D; Watanabe KA; Seidman MM; George J
J Invest Dermatol; 1998 Apr; 110(4):428-37. PubMed ID: 9540987
[TBL] [Abstract] [Full Text] [Related]
